Trial of pimavanserin in dementia-related psychosis
New England Journal of Medicine — Tariot PN, Cummings JL, Soto-Martin ME, et al. | July 26, 2021
Dementia-related psychosis may be present in patients with dementia due to neurodegenerative disease. Researchers examined how oral 5-HT2A inverse agonist and antagonist pimavanserin affects psychosis related to various causes of dementia. In this phase 3, double-blind, randomized, placebo-controlled discontinuation trial, they included patients with psychosis related to Alzheimer’s disease, Parkinson’s disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia. This trial was stopped early for efficacy. Patients with dementia-related psychosis who had a response to pimavanserin were noted to be at a lower risk of relapse with continuation of the drug than with discontinuation.